Effect of BTXA on Inhibiting Hypertrophic Scar Formation in a Rabbit Ear Model

Area of Science:

• Dermatology
• Wound Healing
• Regenerative Medicine

Background:

• Hypertrophic scar (HS) is a challenging skin condition resulting from injury or inflammation.
• Botulinum toxin type A (BTXA) has emerged as a potential therapeutic agent for HS.
• This study investigates the efficacy and optimal dosage of BTXA in treating HS.

Purpose of the Study:

• To evaluate the effectiveness of BTXA in treating hypertrophic scars.
• To determine the dose-response relationship of BTXA for HS treatment.
• To compare BTXA efficacy with a standard treatment (triamcinolone acetonide).

Main Methods:

• Hypertrophic scars were obtained from rabbits and treated with BTXA or triamcinolone acetonide (TAC).
• Histological examination was used to measure the hypertrophic index (HI).
• Collagen fibrils and fibroblast proliferation were assessed using sirius red staining and Ki67 immunohistochemistry.

Main Results:

• BTXA treatment significantly reduced the hypertrophic index compared to a control group.
• Middle doses of BTXA (1.0, 1.5 IU) demonstrated efficacy comparable to TAC treatment.
• Sirius red staining and Ki67 results showed that BTXA inhibited collagen fibril formation and fibroblast proliferation.

Conclusions:

• BTXA effectively improves hypertrophic scar appearance by inhibiting collagen and fibroblast formation.
• The efficacy of middle-dose BTXA is comparable to TAC, indicating its therapeutic potential.
• BTXA warrants further investigation as a viable treatment option for hypertrophic scars.